170 related articles for article (PubMed ID: 21305612)
1. An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder.
Pierò A; Locati E
Hum Psychopharmacol; 2011 Jan; 26(1):63-71. PubMed ID: 21305612
[TBL] [Abstract][Full Text] [Related]
2. Early symptom change prediction of remission in depression treatment.
Katz MM; Meyers AL; Prakash A; Gaynor PJ; Houston JP
Psychopharmacol Bull; 2009; 42(1):94-107. PubMed ID: 19204654
[TBL] [Abstract][Full Text] [Related]
3. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint.
Pollack MH; Kornstein SG; Spann ME; Crits-Christoph P; Raskin J; Russell JM
J Psychiatr Res; 2008 Oct; 42(14):1176-84. PubMed ID: 18348888
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.
Davidson J; Allgulander C; Pollack MH; Hartford J; Erickson JS; Russell JM; Perahia D; Wohlreich MM; Carlson J; Raskin J
Hum Psychopharmacol; 2008 Aug; 23(6):519-26. PubMed ID: 18478624
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study.
Bellino S; Paradiso E; Bozzatello P; Bogetto F
J Psychopharmacol; 2010 Mar; 24(3):333-9. PubMed ID: 18719047
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials.
Lam RW; Andersen HF; Wade AG
Int Clin Psychopharmacol; 2008 Jul; 23(4):181-7. PubMed ID: 18545055
[TBL] [Abstract][Full Text] [Related]
12. An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder.
Kaplan A; Franzen MD; Nickell PV; Ransom D; Lebovitz PJ
Int J Psychiatry Clin Pract; 2014 Jan; 18(1):11-5. PubMed ID: 23980534
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.
Alaka KJ; Noble W; Montejo A; Dueñas H; Munshi A; Strawn JR; Lenox-Smith A; Ahl J; Bidzan L; Dorn B; Ball S
Int J Geriatr Psychiatry; 2014 Sep; 29(9):978-86. PubMed ID: 24644106
[TBL] [Abstract][Full Text] [Related]
14. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
[TBL] [Abstract][Full Text] [Related]
15. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
Bech P; Kajdasz DK; Porsdal V
Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
[TBL] [Abstract][Full Text] [Related]
16. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
17. The development of new antidepressants: focus on duloxetine and escitalopram.
Huffman JC; Perlis RH
Harv Rev Psychiatry; 2003; 11(1):30-6. PubMed ID: 12866739
[No Abstract] [Full Text] [Related]
18. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
19. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
Berk M; du Plessis AD; Birkett M; Richardt D
Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
Vis PM; van Baardewijk M; Einarson TR
Ann Pharmacother; 2005 Nov; 39(11):1798-807. PubMed ID: 16189284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
